SCHEMBL615849

SCHEMBL615849

Cc1c(Cl)cccc1S(=O)(=O)Nc1ccc2[nH]ccc2c1

nearest known ligand 0.58

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
IDH1 O75874 1/20 0.52
MEN1 O00255 2/20 0.51
KMT2A Q03164 2/20 0.51
HSD11B1 P28845 2/20 0.50
CYP19A1 P11511 2/20 0.48
SLC40A1 Q9NP59 1/20 0.48
GSPT1 P15170 1/20 0.48
DDB1 Q16531 1/20 0.48
CRBN Q96SW2 1/20 0.48
ESR1 P03372 2/20 0.46
HTR6 P50406 2/20 0.46
EDNRB P24530 1/20 0.45
EDNRA P25101 1/20 0.45
BRD4 O60885 1/20 0.45
PKM P14618 1/20 0.45
SLC22A12 Q96S37 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL617497 0.90 ESR1 (0.58) IDH1MEN1KMT2AHSD11B1CYP19A1
SCHEMBL616758 0.83 HSD11B1 (0.53) MEN1KMT2AHSD11B1SLC40A1GSPT1
SCHEMBL5347991 0.81 MEN1 (0.78) MEN1KMT2AHSD11B1SLC40A1PKM
SCHEMBL616421 0.79 HSD11B1 (0.51) MEN1KMT2AHSD11B1SLC40A1GSPT1
SCHEMBL4878418 0.79 ESR1 (0.55) MEN1KMT2ACYP19A1ESR1HTR6
SCHEMBL4007842 0.79 HTR6 (0.56) IDH1CYP19A1HTR6BRD4
SCHEMBL618067 0.78 BRD4 (0.56) MEN1KMT2AHSD11B1SLC40A1GSPT1
SCHEMBL31701332 0.78 ESR1 (0.61) IDH1MEN1KMT2ACYP19A1SLC40A1
SCHEMBL615315 0.76 TP53 (0.58) MEN1KMT2AHSD11B1SLC40A1GSPT1
SCHEMBL7578851 0.76 HSD11B1 (0.58) IDH1MEN1KMT2AHSD11B1SLC40A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120041207-A1 Compound STERIX LIMITED (GB) 2012-02-16 US disclosed
US-20120041207-A1 Compound STERIX LIMITED (GB) 2012-02-16 US disclosed
US-20110009448-A1 Compound STERIX LIMITED 2011-01-13 US disclosed
US-20110009448-A1 Compound STERIX LIMITED 2011-01-13 US disclosed
US-7786152-B2 Compound STERIX LIMITED (GB) 2010-08-31 US disclosed
US-7786152-B2 Compound STERIX LIMITED (GB) 2010-08-31 US disclosed
US-7786152-B2 Compound STERIX LIMITED (GB) 2010-08-31 US disclosed
US-20080114042-A1 Inhibiting 11 beta-hydroxysteroid dehydrogenase (11 beta-HSD); use of sulfonamide-substituted N-heterocyclics including pyrroles, oxazoles, thiazoles, imidazoles and their fused analogs to treat diabetes, obesity, hypertension, arthritis, asthma, osteoporosis, breast cancer STERIX LIMITED (GB) 2008-05-15 US disclosed
US-20080114042-A1 Inhibiting 11 beta-hydroxysteroid dehydrogenase (11 beta-HSD); use of sulfonamide-substituted N-heterocyclics including pyrroles, oxazoles, thiazoles, imidazoles and their fused analogs to treat diabetes, obesity, hypertension, arthritis, asthma, osteoporosis, breast cancer STERIX LIMITED (GB) 2008-05-15 US disclosed
US-20080114042-A1 Inhibiting 11 beta-hydroxysteroid dehydrogenase (11 beta-HSD); use of sulfonamide-substituted N-heterocyclics including pyrroles, oxazoles, thiazoles, imidazoles and their fused analogs to treat diabetes, obesity, hypertension, arthritis, asthma, osteoporosis, breast cancer STERIX LIMITED (GB) 2008-05-15 US disclosed
US-7309715-B2 Compound STERIX LIMITED (GB) 2007-12-18 US disclosed
US-7309715-B2 Compound STERIX LIMITED (GB) 2007-12-18 US disclosed
US-7309715-B2 Compound STERIX LIMITED (GB) 2007-12-18 US disclosed
EP-1556040-A1 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 AND TYPE 2 Sterix Limited (GB) 2005-07-27 EP disclosed
US-20040143124-A1 Compound STERIX LIMITED (GB) 2004-07-22 US disclosed
WO-2004037251-A1 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 AND TYPE 2 STERIX LIMITED (GB) 2004-05-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080114042-A1 Inhibiting 11 beta-hydroxysteroid dehydrogenase (11 beta-HSD); use of sulfonamide-substituted N-heterocyclics including pyrroles, oxazoles, thiazoles, imidazoles and their fused analogs to treat diabetes, obesity, hypertension, arthritis, asthma, osteoporosis, breast cancer HSD11B1, HSD3B1, HSD11B2 IDH1 254/4885MEN1 2589/4885KMT2A 2403/4885
US-20110009448-A1 Compound NR4A1, GPR6, PRMT6 IDH1 1081/4885MEN1 1034/4885KMT2A 758/4885
US-20120041207-A1 Compound NR4A1, GPR6, PRMT6 IDH1 1081/4885MEN1 1034/4885KMT2A 758/4885
US-20040143124-A1 Compound NR4A1, CBR1, NR2C2 IDH1 1018/4885MEN1 1105/4885KMT2A 765/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.